Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis

Am J Respir Crit Care Med. 2010 Oct 15;182(8):1047-57. doi: 10.1164/rccm.201001-0010OC. Epub 2010 Jun 17.


Rationale: Sepsis refers to the clinical syndrome of severe systemic inflammation precipitated by infection. Despite appropriate antimicrobial therapy, sepsis-related morbidity and mortality remain intractable problems in critically ill patients. Moreover, there is no specific treatment strategy for the syndrome of sepsis-induced multiple organ dysfunction.

Objectives: We hypothesized that mesenchymal stem cells (MSCs), which have been shown to have immunomodulatory properties, would reduce sepsis-induced inflammation and improve survival in a polymicrobial model of sepsis.

Methods: Sepsis was induced in C57Bl/6J mice by cecal ligation and puncture (CLP), followed 6 hours later by an intravenous injection of MSCs or saline. Twenty-eight hours after CLP, plasma, bronchoalveolar lavage fluid and tissues were collected for analyses. Longer-term studies were performed with antibiotic coadministration to assess the effect of MSCs on survival.

Measurements and main results: MSC treatment significantly reduced mortality in septic mice receiving appropriate antimicrobial therapy. MSCs alone reduced systemic and pulmonary cytokine levels in mice with CLP-induced sepsis, preventing acute lung injury and organ dysfunction, despite the low levels of cell persistence. Microarray data highlighted an overall down-regulation of inflammation and inflammation-related genes (such as IL-10, IL-6) and a shift toward up-regulation of genes involved in promoting phagocytosis and bacterial killing. Finally, bacterial clearance was significantly greater in MSC-treated mice, in part due to enhanced phagocytotic activity of the host immune cells.

Conclusions: These data demonstrate that MSCs have beneficial effects on experimental sepsis, possibly by paracrine mechanisms, and suggest that immunomodulatory cell therapy may be an effective adjunctive treatment to reduce sepsis-related morbidity and mortality.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / genetics
  • Acute Lung Injury / immunology
  • Acute Lung Injury / therapy*
  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Combined Modality Therapy
  • Female
  • Gene Expression Regulation
  • Immunomodulation
  • Inflammation / genetics
  • Inflammation / therapy
  • Mesenchymal Stem Cell Transplantation*
  • Mice
  • Mice, Inbred C57BL
  • Multiple Organ Failure / genetics
  • Multiple Organ Failure / immunology
  • Multiple Organ Failure / therapy*
  • Sepsis / genetics
  • Sepsis / immunology
  • Sepsis / therapy*
  • Survival Analysis


  • Anti-Bacterial Agents